Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

New US Venture

29 Apr 2005 07:01

Angle PLC29 April 2005 For Immediate Release 29 April 2005 ANGLE PLC ESTABLISHMENT OF NEW US VENTURE ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce the establishment of itslatest US-based venture, currently named ContraSoft. ANGLE has securedintellectual property for ContraSoft in the field of computer software testingdeveloped by a team led by Dr. William Rogers. Under the new agreement, ANGLE has an option to intellectual property (IP)developed by Dr. Rogers. This IP offers the potential to change the approachused worldwide for software testing, with substantial improvements inproductivity, reduced costs and improved software quality. The market forsoftware testing tools was over $1.0 billion in 2004 and is projected to grow at9.3 per cent. per annum from 2003 to 2008 according to market research firm IDC. In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE'splan is to undertake the technology commercialisation and product launchbuilding value in ContraSoft. Dr. Rogers has been active in many different aspects of the computer industry,including software development, corporate management, research, and teaching.Dr. Rogers was previously an Assistant Professor of Electrical and ComputerEngineering with the University of Texas. He has also taught courses forbusinesses including IBM, Motorola, Hewlett Packard, Agilent and AMD. Dr.Rogers has had previous commercial success, having owned and run a small companyand managed research and development for a small multinational software company.He received his Master's and PhD from the University of Illinois atUrbana-Champaign and his BSE from Tulane University. ANGLE's Chief Executive Andrew Newland said: "We are delighted to be working with Dr. Rogers to bring this excitingtechnology to market. We believe the software testing market is a substantial,fast growing market long over due for a new approach." Dr. William Rogers commented, "The ANGLE model of combining management expertise and initial capital was veryattractive to me. I think it is a unique model and will accelerate thedevelopment of the company." For further information: ANGLE plcAndrew Newland, Chief Executive +44 (0)1483 295830Dawson Buck, Deputy Chief Executive Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.